Favipiravir

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Favipiravir
Accession Number
DB12466  (DB06046)
Type
Small Molecule
Groups
Investigational
Description

Favipiravir has been investigated for the treatment of Influenza. It is a unique viral RNA polymerase inhibitor, acting on viral genetic copying to prevent its reproduction.

Structure
Thumb
Synonyms
Not Available
External IDs
T-705
Categories
Not Available
UNII
EW5GL2X7E0
CAS number
259793-96-9
Weight
Average: 157.104
Monoisotopic: 157.028754544
Chemical Formula
C5H4FN3O2
InChI Key
ZCGNOVWYSGBHAU-UHFFFAOYSA-N
InChI
InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
IUPAC Name
6-fluoro-3-hydroxypyrazine-2-carboxamide
SMILES
NC(=O)C1=NC(F)=CN=C1O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Favipiravir differs from currently approved anti-influenza drugs, in that it targets influenza viral polymerase. It has been suggested that host cell enzymes (cellular kinases) convert Favipiravir into Favipiravir ribofuranosyl phosphate, a form that inhibits virus polymerase without affecting host cellular RNA or DNA synthesis.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Beigel J, Bray M: Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. doi: 10.1016/j.antiviral.2008.01.003. Epub 2008 Feb 4. [PubMed:18328578]
  2. Hsieh HP, Hsu JT: Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42. [PubMed:18220789]
  3. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW: In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007 Sep;51(9):3168-76. Epub 2007 Jul 2. [PubMed:17606691]
  4. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y: Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007 Mar;51(3):845-51. Epub 2006 Dec 28. [PubMed:17194832]
  5. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K: Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005 Mar;49(3):981-6. [PubMed:15728892]
  6. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K: In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002 Apr;46(4):977-81. [PubMed:11897578]
External Links
PubChem Compound
492405
PubChem Substance
347828705
ChemSpider
431002
ChEBI
134722
ChEMBL
CHEMBL221722
Wikipedia
Favipiravir

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers / Hepatic Impairment1
1, 2CompletedTreatmentFlu caused by Influenza1
2CompletedTreatmentCritical Illness / Flu caused by Influenza / Influenza, Human1
2CompletedTreatmentEbola Virus Disease2
2CompletedTreatmentFlu caused by Influenza1
2TerminatedTreatmentEbola Virus Survivor1
3CompletedTreatmentFlu caused by Influenza2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility8.7 mg/mLALOGPS
logP0.49ALOGPS
logP0.25ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)9.39ChemAxon
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area89.1 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity33.98 m3·mol-1ChemAxon
Polarizability12.12 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrazinecarboxamides. These are compounds containing a pyrazine ring which bears a carboxamide.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrazines
Direct Parent
Pyrazinecarboxamides
Alternative Parents
2-heteroaryl carboxamides / Aryl fluorides / Vinylogous amides / Heteroaromatic compounds / Primary carboxylic acid amides / Lactams / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds
show 3 more
Substituents
Pyrazinecarboxamide / 2-heteroaryl carboxamide / Aryl fluoride / Aryl halide / Vinylogous amide / Heteroaromatic compound / Carboxamide group / Lactam / Primary carboxylic acid amide / Carboxylic acid derivative
show 11 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:30 / Updated on June 04, 2019 07:38